



(RESEARCH ARTICLE)



## Comparative study of I.V. magnesium sulphate and lignocaine for attenuating the haemodynamic stress during laryngoscopy and intubation

Ram Manohar Reddy P \* and Siddartha Patta

*Department of Anaesthesiology, NRI Medical College, Guntur A.P, India.*

International Journal of Science and Research Archive, 2023, 08(02), 037–047

Publication history: Received on 18 January 2023; revised on 27 February 2023; accepted on 02 March 2023

Article DOI: <https://doi.org/10.30574/ijrsra.2023.8.2.0201>

### Abstract

**Background:** Following induction of general anesthesia, laryngoscopy and endotracheal intubation produce pressor response that are somatic visceral reflexes brought on by stimulation of epipharynx and laryngopharynx. To avoid hemodynamic responses to intubation, several strategies have been tested. Agents like opioids, local anesthetics have been used to attenuate such response. Our study was employed with intravenous magnesium sulphate and lignocaine.

**Methods:** A total of 60 patients of both sexes in the age group between 15-50years, belonging to ASA grade I and II undergoing elective surgery under general anaesthesia. Out of the 60 patients 30 were randomly included in the L group (lignocaine group) and the other 30 were included in the M group (magnesium sulphate group).

**Results:** There was fall in heart rate ( $p < 0.05$ ) noted following induction, laryngoscopy, and intubation, in Magnesium group and Lignocaine group, but the fall in heart rate was more significant in the Magnesium group when compared with the Lignocaine group

Like heart rate there was a significant fall in mean arterial pressure in both the groups, but there was statistically significant fall ( $p < 0.05$ ) in the Magnesium group when compared with the Lignocaine group.

**Keywords:** Magnesium sulphate; Lignocaine; Intubation response; Cardiovascular response

### 1. Introduction

Haemodynamic stress response to laryngoscopy and intubation occurs as increase in the heart rate and the mean arterial pressure due to reflex sympathetic discharge in response to laryngo-tracheal stimulation<sup>1</sup>.

Tracheal intubation alters respiratory and cardiovascular physiology by reflex response and also by the physical presence of endotracheal tube. Although these circulatory responses are transient and of little consequence in patients with normal circulatory system, they may be exaggerated in patients with coronary artery disease, reactive airways and intracranial pathology. This transitory variable and unpredictable response is mediated by both sympathetic and parasympathetic nervous systems. Usually bradycardia seen in neonates and infants during laryngoscopy and intubation is the autonomic equivalent of laryngo-spasm response in adults. This reflex is mediated by an increase in vagal tone at the SA node and is virtually a monosynaptic response to anoxic stimuli in the airway.<sup>2,4</sup> The more common response to tracheal intubation is hypertension and tachycardia mediated by sympathetic efferents via the cardio accelerator nerves and sympathetic chain ganglia. The polysynaptic nature of pathways from the IX and X nerve afferents to the sympathetic nervous system via the brain stem and spinal cord results in a diffuse autonomic response which includes widespread release of norepinephrine from the adrenergic terminals and release of epinephrine from

\*Corresponding author: Ram Manohar Reddy P

the adrenal medulla. One other reason for the hypertensive response is due to activation of renin-angiotensin system with release of renin from the renal juxtaglomerular apparatus, an end organ innervated by adrenergic nerve terminals. Magnesium sulphate blocks the release of catecholamines from the adrenergic nerve terminals and adrenal glands.

### *Aims and objectives*

This study was done to:

- To compare the efficacy of Magnesium Sulphate and Lignocaine in attenuating the cardiovascular responses to laryngoscopy and intubation.
- To observe any adverse effects of Magnesium sulphate in the specified dosage.
- To observe any prolongation of neuromuscular blockade in this specified dose.

---

## **2. Material and methods**

After approval of the study by our institutional Ethics Committee, a total of 60 patients of both sexes in the age group between 15-50 years, belonging to ASA grade I and II undergoing elective surgery under general anaesthesia during the period of May 2022 to October 2022 were included in this double blinded, randomized, clinical study. Informed written consent was obtained from all the patients. Patients were assessed by detailed history and physical examination, supported by routine investigations (Haemoglobin percentage, Blood glucose, urea, creatinine, ECG, X-ray chest PA view).

### **2.1. Inclusion criteria**

Patients belonging to ASA grade-I and II, MP grade-I and II, and laryngoscopy time less than 15seconds.

### **2.2. Exclusion criteria**

Patients belonging to ASA grade more than two., MPG > II, predicted difficult airway, systemic hypertension, coronary artery heart disease, obesity, diabetes mellitus, patients on antihypertensives and cardiac drugs, and valvular heart diseases.

Out of the 60 patients 30 were randomly included in the L group (**LIGNOCAINE GROUP**) and the other 30 were included in the M group (**MAGNESIUM SULPHATE GROUP**).

All the patients were premedicated with injection Glycopyrolate 0.10 mcg/kg intramuscularly 45minutes prior to surgery. Patients were shifted to the operation theatre and connected to the noninvasive multichannel monitor, and intravenous access secured using 18G cannula.

Baseline Heart rate, Blood pressure (Mean arterial pressure), SPO2 were recorded.

The patients were preoxygenated with 100% oxygen for 3 minutes. All the patients received injection Fentanyl 1mcg/kg intravenously. Two minutes after the administration of fentanyl, patients in L group received injection Lignocaine 1.5mg/kg and the patients in the M group received injection Magnesium sulphate 30mg/kg intravenously. One minute after that the patients were induced with injection Thiopentone 5mg/kg and injection vecuronium 0.08mg/kg intravenously. Then the patients were mask ventilated with 100% oxygen and after 3 minutes heart rate, blood pressure (mean arterial pressure) were noted and taken as the post induction value. Laryngoscopy and intubation was done using appropriate size Macintosh blade and appropriate size endotracheal tube. Measurement of heart rate, blood pressure (Mean arterial pressure) and SPO2 was done immediately after laryngoscopy and at one, three and five minutes after placement of the endotracheal tube. Surgical incision was allowed after the last measurement. Syringes were prepared by a postgraduate who did not take part in the study and the injections were given by him. Intubation was performed by an experienced anaesthesiologist who was double blinded to the drugs given. Neuromuscular blockade was monitored using the nerve stimulator with train of four for every 5 minutes after intubation upto 45minutes.

The incidence of complications like hypotension, arrhythmias, nausea, flushing, sweating were recorded until the patient was discharged from the post anaesthesia care unit.


### 2.3. Statistical Analysis

Statistical analysis was done using SPSS version 20.0. Students independent “t” test was used to compare various factors between the two groups. Results were expressed as mean and standard deviation(Mean±SD)Chi-square test was done to compare proportions, and p values less than 0.05 was considered as statistically significant.

### 3. Results

**Table 1** Demographic characters between groups

Parameters	Group - L(n=30)	Group - M(n=30)	Pvalue
Mean Age in Years(±S.D)	33.17±8.05	33.43 ±7.82	0.8995
Mean weight in Kgs(±SD)	54.53 ±3.33	53.93 ±4.19	0.5416
S.D-Standard Deviation	(p>0.05)		




**Figure 1** Demographic characters between groups

The groups were matched for demographic data, and there was no statistically significant difference found between the groups in age, weight (Table 1)(Figure 1).

With patient on table before giving Lignocaine or Magnesium sulphate, baseline heart rate and mean arterial pressure were recorded for the two groups (Table:2) (Figure 2) and(Table:3) (Figure 3)respectively. There was no significant difference in heart rate and MAP between the 2 groups.

**Table 2** Baseline heart rate


Base Line H.R.	Group- L	Group-M
Mean ±S.D	87.17±6.56	85.83±6.35
HR-HeartRate	(P=0.4268)	



**Figure 2** Base line heart rate

**Table 3** Base line mean arterial pressure


Base Line MAP	Group- L	Group-M
Mean $\pm$ S.D	92.03 $\pm$ 9.75	83.83 $\pm$ 8.78
MAP-Mean Arterial Pressure	(P=0.455)	



**Figure 3** Base line mean arterial pressure

**Table 4** Deviation of heart rate from baseline

Heart Rate	Group - L Mean $\pm$ S.D	Group - M Mean $\pm$ S.D	Pvalues
Post Induction	81.07 $\pm$ 6.79	73.13 $\pm$ 14.25	0.0079
PostLaryngoscopy	84.77 $\pm$ 6.06	78.23 $\pm$ 5.08	0.0001
Post Intubation(1Min)	86.3 $\pm$ 36.32	78.57 $\pm$ 4.45	0.0001
Post Intubation(3Min)	84.80 $\pm$ 5.97	75.10 $\pm$ 4.29	0.0001
Post Intubation(5Min)	83.47 $\pm$ 6.27	72.77 $\pm$ 3.98	0.0001
			P < 0.05




**Figure 4** Deviation of heart rate from baseline

After the drug was administered intravenously any deviation from the baseline values were recorded following induction, laryngoscopy, and intubation.(1minute, 3minutes,and 5minutes)(Table:4,Table:5)

There was fall in heart rate ( $P < 0.05$ ) noted following induction, laryngoscopy, and intubation, in Magnesium group and Lignocaine group, but the fall in heart rate was more significant in the Magnesium group when compared with the Lignocaine group. Figure 4.

**Table 5** Deviation of mean arterial pressure from baseline

MAP (Mean Arterial Pressure)	Group - L Mean $\pm$ S.D	Group - M Mean $\pm$ S.D	P values
Post Induction	86.3 $\pm$ 8.47	81.60 $\pm$ 8.14	0.0313
Post Laryngoscopy	90.07 $\pm$ 8.91	84.43 $\pm$ 7.82	0.0117
Post Intubation (1 Min)	88.70 $\pm$ 8.95	79.83 $\pm$ 7.34	0.0001
Post Intubation (3 Min)	88.70 $\pm$ 8.95	79.83 $\pm$ 37.34	0.0001
Post Intubation (5 Min)	86.50 $\pm$ 8.37	78.03 $\pm$ 7.10	0.0001
			$P < 0.05$




**Figure 5** Deviation of mean arterial pressure from baseline

Like heart rate there was a significant fall in mean arterial pressure in both the groups, but there was statistically significant fall ( $P < 0.05$ ) in the Magnesium group when compared with the Lignocaine group. Figure 5

**Table 6** Average Values Of Train Of Four r

TOF in Minutes	Group- L	Group-M	PValue
Mean± S.D	25.5 ± 4.84	26.5 ± 4.89	0.52
	( $P > 0.05$ )		



**Figure 6** Average Values of Train Of Four

The train of four values were recorded every 5 minutes upto 45 minutes following drug administration and the duration needed for the return of third twitch using neuromuscular monitoring was recorded. This showed no statistically significant difference between the 2 group ( $P > 0.05$ ). (Figure 6)

The incidence of complications for magnesium like hypotension, sweating, arrhythmia, nausea, flushing were watched for until the patients were discharged from post anaesthesia care unit. There were no such complications observed in this study.

#### 4. Discussion

Laryngoscopy and endotracheal intubation can cause striking changes in haemodynamic and intracranial pressure probably as a result of intense sympathetic nervous system stimulation<sup>36</sup>. In patients who are at risk of developing increased intracranial pressure, arterial hypertension, myocardial ischemia and these changes may be life threatening. They may lead to cerebral haemorrhage, left ventricular failure and life threatening cardiac arrhythmias. Various techniques were tried to attenuate these cardiovascular responses, one of them being deep inhalational anaesthesia which may cause intracranial hypertension. The other technique being the administration of a large dose of thiopental sodium which can effectively prevent arterial and intracranial hypertension, but in these cases there are risks of cardiac depression. Potent vasodilator drugs need larger doses to attenuate arterial blood pressure and fail to prevent tachycardia caused by laryngoscopy and endotracheal intubation. Vasodilator drugs cause cerebral hypertension. Some of them cause hypertension with reflex tachycardia and others depress the myocardium severely in patients with preexisting left ventricular dysfunction or those receiving beta adrenergic antagonist. These effects are not desirable and limit their usefulness. Various studies have shown that intravenous lignocaine is effective in preventing or attenuating the arterial hypertension and tachycardia in response to endotracheal intubation<sup>37</sup>. Some publications have shown attenuated haemodynamic responses on intubation with intravenous lignocaine<sup>38,39</sup>.

Kim et al <sup>40</sup> and Fuji et al <sup>41</sup> carried out several randomized open studies on adult surgical patients to assess the effect of intravenous lignocaine. They also found reduced haemodynamic stimulation during intubation.

Calcium exerts a major role in stimulus-response relationship, including the release of catecholamines from the adrenal gland and adrenergic nerve terminals in response to sympathetic stimulation. Because Magnesium competes with calcium for membrane channels, it has been described as the physiological calcium antagonist and can modify many calcium mediated responses.<sup>42</sup>

The ability of magnesium ion in inhibiting the release of catecholamines has long been recognized, hence it is considered for use in laryngoscopy and intubation to minimize cardiovascular responses.<sup>43,44</sup>

Fawcett WJ, Haxby EJ, Male DA <sup>43</sup> showed that in those using magnesium , an increase in systolic blood pressure compared to baseline value occurred in the first minute of intubation; where as in the lidocaine group this increase was significant for the first two minutes. Clearly, intubation does cause an increase in systolic pressure, but variables gradually return to normal. Although diastolic blood pressure after intubation increased in both groups, this increase was not significant in either group compared to baseline value. These results may be explained by the fact that magnesium causes vasodilatation directly and also indirectly by sympathetic ganglia blockage and inhibition of release of catecholamines. The difference in mean systolic blood pressure between the two groups can be explained by the effect of magnesium on transient reduction of Systemic Vascular Resistance (SVR) in combination with reduced arterial pressure. Findings of this study regarding heart rate in the two groups indicate that, in addition to a reduction in SVR after administration of magnesium, increased heart rate may be due to inhibition of release of acetylcholine from vagal nerves.

On comparison with our study, in which we used Magnesium sulphate in the dose of 30mg/kg intravenously to assess the cardiovascular response to laryngoscopy and intubation showed a decrease in heart rate (  $P < 0.005$ ) and the mean arterial pressure also showed a decrease (  $P < 0.05$ ) on comparison with the Lignocaine group.

G.D. Puri et.al. <sup>30</sup>in their study on the effect of Magnesium sulphate on haemodynamics and its efficiency in attenuating the response to endotracheal intubation in patients with coronary artery disease, studied 36 patients, of which one group received 50mg/kg of Magnesium sulphate intravenously and another group received 1mg/kg Lignocaine intravenously.

Their results showed a decrease in mean arterial pressure from basal values of  $91 \pm 14.5$  to  $86.6 \pm 14.5$  mm of Hg after intubation ( $P < 0.05$ ). The heart rate showed a mild increase from  $65.2 \pm 12.7$  to  $69.7 \pm 13.7$  beats/ minute ( $P < 0.001$ ), and the cardiac index is also increased ( $P < 0.01$ ) in the Magnesium sulphate group when compared with control group.

Three patients in the magnesium group and two patients in the control group had severe hypotension that needed pharmacological treatment. This fall was noted in the patients who were taking ACE inhibitors or beta-blockers for coronary artery disease and this potentiated the myocardial depressing effect of Magnesium sulphate. In this study all the patients were ventilated post operatively, so the enhancing effect of neuromuscular blockade was not studied.

In comparison with our study, in which we used Magnesium sulphate in the dose of 30mg/kg intravenously to assess the cardiovascular response to laryngoscopy and intubation showed a decrease in heart rate ( $P < 0.005$ ) and the mean arterial pressure also showed a decrease ( $P < 0.05$ ) on comparison with the Lignocaine group.

The increase in the heart rate noted in this study by G.D.Puri et.al.<sup>30</sup> may be due to the ability of Magnesium sulphate in higher doses to inhibit the release of acetylcholine from the vagal nerve predominantly.

This theory was supported by Michael F.M. James, FFARCS, R. Eryk Beer, FFA(SA), and Jan D. Esser, MMED<sup>29</sup> in their study, "Intravenous Magnesium sulphate inhibits catecholamine release associated with tracheal intubation" in which they used Magnesium sulphate in the dose of 60mg/kg intravenously and their results showed an initial increase in heart rate by  $13 \pm 3.9$  beats/ minute.

This effect was not observed in our study as we used a dose of 30mg/kg, which was a lesser dose on comparison with their study.

The mean arterial pressure in both studies showed a declining trend, but three patients in the Magnesium sulphate group in their study showed hypotension which required treatment, which was not observed in our study since we

included majority ASA grade I patients, who were not on any drugs acting on cardiovascular system preoperatively. However we should be aware of the adverse haemodynamic interactions of Magnesium sulphate in patients receiving cardiovascular drugs like ACE inhibitors, betablockers and calciumchannel blockers.

In a dose response study of Magnesium sulphate in suppressing the cardiovascular responses to laryngoscopy and intubation done by K.Montazeri M.D., M.Fallah M.D.<sup>33</sup> studied 6 groups of patients of 20 each with varying doses of Magnesium sulphate (10,20,30,40, and 50mg/kg) and compared with the control using Lignocaine in the dose of 1.5mg/kg. and observed that there was significant reduction in heart rate on comparison between Magnesium sulphate and Lignocaine groups ( $P < 0.05$ ). But within the magnesium groups the difference in heart rate was not significant ( $P > 0.05$ ).

The train of four at 45 minutes after induction of anaesthesia in all groups had no statistically significant differences. Adverse effects of Magnesium sulphate like hypotension, arrhythmia, nausea, sweating and flushing, were observed in certain patients in higher doses.

Similarly in our study using 30mg/kg of Magnesium sulphate there was a reduction in the heart rate ( $P < 0.05$ ) and the mean arterial pressure ( $P < 0.05$ ), which was statistically significant when compared with the lignocaine group lending support to our study. We did not observe any side effects in any of the patients. Similarly neuromuscular blockade was not significantly prolonged in our study as seen by the train of four values at 45 minutes.

Like heart rate there was significant fall in the mean arterial pressure when compared with the lignocaine group ( $P < 0.05$ ), but the fall is not significant within the magnesium groups ( $P > 0.05$ ).

In a study by G.M. Saunders FRCA, K.M. Sim M.Md (Anaes),<sup>32</sup> "Is it Feasible to use Magnesium sulphate as hypotensive agent in oral and maxillo facial surgery.

Studied 16 patients using Magnesium sulphate infusion at 40g/hr until the mean arterial pressure reached to  $55 \pm 5$  mm Hg and followed by maintenance of 5g/hr until 30 min. prior to the end of surgery, their results showed decrease in mean arterial pressure and heart rate from a baseline during the surgery and which returned to baseline 26 minutes after the surgery.

Train of four monitoring during surgery showed no response in all the patients on Magnesium sulphate infusion. On terminating the Magnesium sulphate infusion the first tetanic contraction appeared with no fade, followed by train of four pattern similar to that seen with depolarizing neuromuscular blockers. There were no complications like reflex tachycardia or arrhythmias observed.

This study corroborates with our study in the reduction of mean arterial pressure and heart rate significantly in intravenous use of Magnesium sulphate, but we altered the dose to 30mg/kg bolus, as they have used higher doses and observed few side effects like prolonged sedation postoperatively.

In another study by R.W. Allen, M.B., CH.B., F.F.A.R.C.S.I, M.F.M. James, CH.B., P.C. Uys, CH.b. FFA (SA)<sup>27</sup> in "Attenuation of the pressor response to tracheal intubation in hypertensive proteinuric pregnant patients by Lignocaine, Alfentanil, and Magnesium sulphate". They used Magnesium sulphate 40mg/kg intravenously and observed an increase in the systolic, diastolic blood pressure and mean arterial pressure following intubation, in the lignocaine group when compared to the Magnesium group. Similarly the heart rate was decreased in the Magnesium sulphate group significantly when compared to the other two groups. Alfentanil caused least change in heart rate but caused significant fetal depression. Although Magnesium sulphate and Alfentanil provide adequate control of cardiovascular response in hypertensive patients, Alfentanil is less reliable in controlling severe hypertension.

This study corroborates with the evidences in our study that Magnesium sulphate intravenously given prior to induction can have adequate control of cardiovascular response to laryngoscopy and intubation.

Our present study lends support to previous studies that the use of Magnesium sulphate 30mg/kg intravenously one minute prior to induction reduces the heart rate and mean arterial pressure in response to laryngoscopy and intubation in a favourable manner without any side effects.



---

## 5. Conclusion

We conclude that, Magnesium sulphate in the dose of 30mg/kg given intravenously one minute prior to induction,

- Attenuates the cardiovascular responses to laryngoscopy and intubation in a better manner than lignocaine.
- Does not cause any adverse effects in any of the patients.
- Does not cause prolongation of the neuromuscular blockade.

---

## Compliance with ethical standards

### *Acknowledgments*

We would like to thank all the participants and department of Anaesthesiology NRI MEDICAL COLLEGE for helping in the study.

### *Disclosure of conflict of interest*

We have no conflict of interest to declare in this study.

### *Statement of ethical approval*

This study doesn't harm any individual involved.

### *Statement of informed consent*

All information and statements obtained from respondents (informants) are for research purposes and will be maintained.

---

## References

- [1] Thomas EJ Healy, Paul R Knight. Principles of airway management. In Wyle Churchill Davidson ; Practice of anaesthesiology, 7th edition, Arnold publishers 2003; 28; pp 452-453
- [2] Stoelting RK. Circulatory changes during direct laryngoscopy and tracheal intubation: influence of duration of laryngoscopy with or without lidocaine. *Anaesthesiology* 1977; 47: 381-84
- [3] Kovac AL. Controlling the hemodynamic response to laryngoscopy and endotracheal intubation. *J Clin Anesth.* 1996;8(1):63-79.
- [4] Figueredo E, Garcia-Fuentes EM. Assessment of the efficacy of esmolol on the haemodynamic changes induced by laryngoscopy and tracheal intubation: a meta-analysis. *Acta Anaesthesiol Scand.* 2001;45(8):1011-22.
- [5] Harold Ellis- ANATOMY FOR ANAESTHETISTS, CBE, MA, DM, FRCS, FACS (Hon ). ; p 17 - 37.
- [6] Miller's Anaesthesia- 6th edition - Ronald D. Miller, p 1634.
- [7] Bernhard GC, Bohm E, Hojeberg S. A new treatment of status epilepticus: intravenous injections of a local anaesthetic (lidocaine).
- [8] De Giorgio CM, Altman K, Hamilton-Byrd E, et al. Lidocaine in refractory status epilepticus: confirmation of efficacy with continuous EEG monitoring. *Epilepsia* 1992;33:913-16.
- [9] Fawcett WJ, Haxby EJ, Male DA. Magnesium: physiology and pharmacology. *J Anaesth* 1999 Aug;83(2):302-20.
- [10] D. Watanabe and H. Hamaguchi. The dynamic structure of the sulfate ion in aqueous solution Studied by Raman Bandshape analysis Department of Chemistry, School of Science, The University of Tokyo; Lett. 339, 351 (2001).
- [11] Magee LA, Ornstein MP, von Dadelszen P. management of hypertension in pregnancy. *BMJ.* 1999;318(7194):1332-6.
- [12] Sibai BM. Magnesium sulfate prophylaxis in preeclampsia: Lessons learned from recent trials. *Am J Obstet Gynecol.* 2004;190(6):1520-6.

- [13] Wilkins IA, Lynch L, Mehalek KE et al. efficacy and side effects of magnesium sulfate and ritodrine as tocolytic agents. *Am J Obstet gynecol.* 1988; 159:685-9.
- [14] Emerson CE, Rainbird A. Use of a „hospital-at-home“ service for patient optimization before resection of pheochromocytoma. *Br J Anaesth* 2003;90:380–2.
- [15] Flather M, Pipilis A, Collins R, Budaj A, Hargreaves A, Kolettis T, et al. Randomized controlled trial of oral captopril, of oral isosorbide mononitrate and of intravenous magnesium sulphate started early in acute myocardial infarction: safety and haemodynamic effects. ISIS-4 (Fourth International Study of Infarct Survival) Pilot Study Investigators. *Eur Heart J.* 1994;15(5):608–19.
- [16] Johnson CH, van Tassell VJ. Acute barium poisoning with respiratory failure and rhabdomyolysis. *Ann Emerg Med.* 1991;20:1138- 42.
- [17] Kowal A, Panaszek B, Barg W, Obojski A. The use of magnesium in bronchial asthma: a new approach to an old problem. *Arch Immunol Ther Exp (Warsz)* 2007;55:35–39. The American Heart Association. Guidelines 2005 for cardiopulmonary resuscitation and emergency cardiovascular care. *Circulation.* 2005; 112(Suppl I):IV1-211.
- [18] Attygalle D, Rodrigo N: Magnesium as first line therapy in the management of tetanus: A prospective study of 40 patients. *Anaesthesia* 2002; 57:778–817.
- [19] Jenkinson DH. The nature of the antagonism between calcium and magnesium ions at the neuromuscular junction. *J Physiol(Lond)*; 138: 434-44.
- [20] AHFS. Drug information. American society of health system pharmacists; 2000: 2169-4.
- [21] Prys Roberts, C Green– Studies of anaesthesia in relation to the hypertension –Haemodynamic consequences of laryngoscopy and intubation – *BJA*; 1971, 43; 531 – 46.
- [22] King B.D., L.C. Harris, F.E. Greitenstein, J.D. Elder, and R.D. Dripps– Reflex circulatory response to direct laryngoscopy and tracheal intubation performed during general anaesthesia – *Anaesthesiology* 1951, 12; 556-62.
- [23] Russell WJ, Morris RG, Frewin DB, Drew SE, changes in plasma catecholamines concentrations during endotracheal intubation. *British journal of anaesthesia* 1981;53:837-9
- [24] MinJH, Chai HS, Kim YH, Chae YK, Choi SS, Lee A, et al. Attenuation of hemodynamic responses to laryngoscopy and tracheal intubation during rapid sequence induction: remifentanyl vs. lidocaine with esmolol. *Anesthesiol.* 2010;76(3):188–92.
- [25] Aries and Simonis *Biochem. pharmacol.*: 32, 1539, 1983.
- [26] A.J. Shribiran, G. Smith et. al., - Cardiovascular and catecholamine responses to laryngoscopy with and without intubation,- *British Journal of Anaesthesia*, 1987, 59; 245 – 9.
- [27] Allen RW, James MF, Uys PC. Attenuation of the pressor response to tracheal intubation in hypertensive proteinuric pregnant patients by lignocaine, alfentanil and magnesium sulphate. *Br J Anaesth* 1991 Feb;66(2):216-23.
- [28] Zijl DH, Gordon PC, James MF. The comparative effects of remifentanyl or magnesium sulphate versus placebo on attenuating the haemodynamic responses after electroconvulsive therapy. *Anesth Analg.* 101:1651-1655.
- [29] Michael F. M. James, FFARCS, R. Eryk Beer, FFA(SA), and Jan D. Esser, MMED, “Intravenous Magnesium Sulfate Inhibits Catecholamine Release Associated with Tracheal Intubation”, *Anesth Analg* 1989; 68:772-776.
- [30] Puri GD, Marudhachalam KS, Chari P, Suri RK. The effect of magnesium sulphate on haemodynamics and its efficacy in attenuating the response to endotracheal intubation in patients with coronary artery disease. *Anesth Analg* 1998 Oct;87(4):808-11
- [31] N. M. Elsharnouby, and M. M. Elsharnouby; Magnesium sulphate as a technique of hypotensive anaesthesia. *British Journal of Anaesthesia* 2006 96(6):727-731.
- [32] G M Sanders, FRCA, K M Sim, M. Is it Feasible to Use Magnesium Sulphate as a Hypotensive Agent in Oral and Maxillofacial Surgery?, *Med (Anaes)*; *Ann Acad Med Singapore* 1998; 27:780-5.
- [33] K. Montazeri M.D., M. Fallah M.D., A Dose – Response study of Magnesium sulphate in suppressing the cardiovascular responses to laryngoscopy and endotracheal intubation. *Journal of Research in Medical Sciences* 2005;10(2):82–86.

- [34] Tetsuro Kagawa 1, Ryokichi Goto 1, Katsuhiro Iijima ], Yuji Kamikawa, Kenchi Sakai , and Hidefumi Obara . Intravenous magnesium sulfate as apreanesthetic medication: A double-blind study on its effects on haemodynamic stabilization at the time of tracheal intubation. *J A.nesth* (1994) 8:17-20.
- [35] Naghibi KH, Akhtari M. Attenuation of the pressor responses to trachealintubation by MgSO<sub>4</sub>. *Res med sci J* 2000;Supp 1:42-44.
- [36] Samaha T, Ravussin P, Claquin C, Ecoffey C. Prevention of increase blood pressure during endotracheal intubation in neurosurgery and surgery: esmolol versus lidocaine. *Ann Fr Anaesth Renim* 1996; 15(1):36-40.
- [37] Morshed AKM et al. Effect of intravenous lignocaine on cardiovascular response during laryngoscopy and endotracheal intubation. *Ban J Med Sc* 2000; 6(2):11-14.
- [38] Miller CD, Warren SJ. IV lignocaine fails to attenuate the cardiovascular response to laryngoscopy and tracheal intubation. *Br J Anaesth.* 1990; 65(2):216-9.
- [39] Sklar BZ, Lurie S, Ezri T , Krichelli D, Savir I, Soroker D. Lignocaine inhalation attenuates the circulatory response to laryngoscopy and endotracheal intubation. *J Clin anesth.* 1992; 4(5):382-5.
- [40] Kim JT, Shim JK , Kim SH, et al. Remifentanil vs. lignocaine for attenuating the haemodynamic response during rapid sequence induction using propofol: double-blind randomized clinical trail.*Anaesth Intensive Care.*2007; 35(1):20-3.
- [41] Fujii et al. Combined diltiazem and lignocaine reduces cardiovascular response to tracheal extubation and anaesthetic emergence in hypertensive patients. *Can J Anaesth* 1999;46(10):952
- [42] Russell WJ, Morris RG , Frewin DB, Drew SE, changes in plasma catecholamines concentrations during endotracheal intubation. *British journal of anaesthesia* 1981;53:837-9.
- [43] Fawcett WJ, Haxby EJ, Male DA. Magnesium: physiology and pharmacology.*J Anaesth*1999 Aug;83(2):302-20.
- [44] James MF, Beer RE, Esser JD. Intravenous magnesium sulfate inhibitscatecholamine release associated with tracheal intubation.*Anesth Analg* 1989 Jun;68(6):772-